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Adenoviral-mediated expression of
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Jonathan C. Fox, MD, PhD, David G. Neschis, MD, Robert W. Hobson II,
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Purpose: The purpose of this study was to test whether basic fibroblast growth factor
(bFGF) participates in arterialized vein graft remodeling.
Methods: Rabbits underwent in vivo gene transfer and carotid interposition vein graft-
ing. Segments of external jugular vein were infected with an adenovirus that expressed
antisense bFGF RNA (Ad.ASbFGF) at 1 × 1010 PFU/mL to inhibit new synthesis of
bFGF by cells in the vein graft wall. Control rabbits were treated with either adenovirus
that encoded β-galactosidase (Ad.lacZ) at 1 × 1010 PFU/mL or vehicle (phosphate-
buffered saline solution [PBS]). At 3 days, 3 grafts per treatment group were harvested
for the determination of gene expression of ASbFGF RNA by reverse transcriptase-
polymerase chain reaction. Rabbits were killed, and perfusion was fixed 2 months after
the grafting. Total wall thickness and lumen circumference of vein grafts and normal
arteries were measured in cross sections. Calculated mean tangential stress (±SD) for the
ASbFGF-treated group and controls was compared for significance. Grafts were
immunohistochemically stained to assess bFGF protein production.
Results: Only the grafts infected with the Ad.ASbFGF gene expressed ASbFGF RNA.
Grafts that were treated with Ad.ASbFGF displayed lower tangential stress (10.9 ± 2.3
dynes/cm2) than PBS alone (22 ± 2.8 dynes/cm2) or Ad.lacZ-treated controls (20.6 ±
5.4 dynes/cm2; P < .001). Tangential stress in the Ad.ASbFGF group was comparable
to a normal carotid artery (13.9 ± 2.1 dynes/cm2). The difference in mean total wall
thickness was significant among the 3 treatment groups: Ad.ASbFGF, 164 ± 3.4 µm);
Ad.lacZ, 100 ± 3.3 µm; and PBS, 96 ± 3.6 µm; P < .01). Luminal circumference was not
different among the groups. The Ad.ASbFGF-treated vein graft wall was composed of
thick layers of concentric smooth muscle cells and elastin fibers in contrast to the
sponge-like appearance observed in control arterialized vein grafts. Reduction in bFGF
protein was noted only in the Ad.ASbFGF-treated group.
Conclusion: Inhibition of bFGF synthesis in vivo with the use of adenoviral gene transfer of
antisense RNA to bFGF promotes a vein graft with decreased tangential stress while main-
taining the luminal area. The vein graft wall is remodeled and qualitatively resembles an
artery so that wall tangential stress in Ad.ASbFGF and normal artery are not significantly
different. The lack of significant difference in lumen circumference among groups suggests
that wall thickening in the Ad.ASbFGF grafts is not at the expense of luminal narrowing.
Our results suggest that ASbFGF RNA expression may represent an effective strategy in
limiting the failure of arterialized venous conduits. (J Vasc Surg 2000;31:770-80.)
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Vein bypass grafting restores blood flow to a
compromised vascular bed, and it leads to the thick-
ening of the vein graft wall.1-4 In response to arteri-
al pressures and pulsatile flow, the vein graft under-
goes an adaptive remodeling process to strengthen
the normally thin vein wall. Exaggeration of this
process in the neointima causes failure of the vein
graft as a conduit. The ideal remodeling process for
arterialized veins would preserve luminal dimen-
sions, while thickening the wall with smooth muscle
cells (SMCs) and elastin fibers. Furthermore, the
SMCs and elastin fibers would be arrayed concentri-
cally for maximal passive and active responses to pul-
satile flow. Thickening of the vein graft wall may
serve to minimize tangential stress.4,5 In this regard,
the ideal proportions of lumen radius to wall thick-
ness are those of a normal artery.
In animal arterialized vein graft (AVG) models,
intimal hyperplasia develops rapidly, with SMC pro-
liferation peaking at 1 week and becoming quiescent
at 3 to 6 months. Because SMC mass does not
increase after 4 weeks after grafting, further increas-
es in wall thickness (observed between 1 and 3
months) are accounted for by the accumulation of
extracellular matrix.4
The tissue remodeling process is modulated by
growth factors. Immunocytochemical evidence indi-
cates that basic fibroblast growth factor (bFGF) and
platelet-derived growth factor are upregulated in
injured arteries and AVGs.6 Although the upregula-
tion of bFGF in newly grafted vein segments is doc-
umented, the significance of continued de novo
bFGF synthesis in AVG walls remains unknown.7-9
We previously tested the possible role of bFGF in
remodeling by inhibiting bFGF production by the
administration of antisense bFGF RNA (ASbFGF)
in a rat aortic SMC culture and in an in vivo model
of injured carotid artery.10,11 In cell culture, anti-
sense RNA administered through the adenoviral
vector (Ad.ASbFGF) reduced cellular bFGF content
and decreased the growth rate of SMC in a dose-
related manner. In addition, ASbFGF altered the
SMC phenotype and appeared to stimulate apopto-
sis, as indicated by positive terminal tdt-deoxyuri-
dine nick-end labeling reaction.10 In Fogarty-bal-
loon–injured carotid arteries, administration of a
single dose of ASbFGF at the time of injury resulted
in decreased neointima formation and the restora-
tion of the media and was dose dependent.11
To test the hypothesis that the inhibition of
bFGF synthesis will beneficially alter the remodeling
process, we extended our studies to an in vivo model
of a vein interposition graft in this work. We rea-
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soned that adenovirally mediated delivery of anti-
sense bFGF RNA at the time of grafting would
block new synthesis of bFGF, providing us with a
research tool to study the molecular and cellular
events of bFGF-dependent AVG remodeling and
perhaps lead to an effective therapeutic intervention. 
METHODS
Rabbit model of interposition vein graft and
in vivo gene transfer. Fifty-one adult male New
Zealand White rabbits that weighed 3 ± 0.1 kg were
anesthetized with an intramuscular injection of ke-
tamine (50 mg/kg; Aveco Co, Fort Dodge, Iowa),
xylazine (5 mg/kg; Mobay Corp, Shawnee, Kan),
and acepromazine (1 mg/kg; Aveco Co). Neither
mechanical ventilation nor supplemental intravenous
fluid administration was required. Twelve AVGs
were constructed to study the time course of bFGF
RNA expression in untreated grafts, although 39
vein grafts received treatment before the grafting.
Common carotid AVGs were performed accord-
ing to published reports.4 Briefly, a 2.5-cm segment
of the external jugular vein, lacking valves, was iso-
lated by ligation of the proximal and distal vein. A
small venotomy was made in the distal vein. After
irrigation with phosphate-buffered saline solution
(PBS), a 250 µL volume of either adenoviral vector
(at 1 × 1010 PFU/mL) in PBS or PBS alone was
injected into the lumen of the isolated vein and
maintained at 120 mm Hg pressure for 30 minutes. 
After systemic heparinization (1000 U; Elkins-
Sinn Inc, Cherry Hill, NJ), the carotid artery was
dissected and clamped. A segment of carotid artery,
equal to the original in situ length of the vein seg-
ment, was excised. The vein segment, free of sur-
rounding tissues, was grafted by end-to-end anasto-
moses with a 9-0 nylon continuous running suture
(Sharpoint Surgical Specialties Corp, Reading, Pa).
Arterial blood flow was restored to the carotid artery
and vein graft. The neck incision was closed in two
layers, and the animals were placed under a warming
light until fully recovered from anesthesia. After
recovery, the rabbits were fed a normal diet and
water as desired. Animal care complied with the
“Principles of Laboratory Animal Care” formulated
by the National Society of Medical Research, and
the “Guide for the Care and Use of Laboratory
Animals” (NIH publication no 86-23, revised
1985).
Construction of Ad.ASbFGF
Recombinant adenoviruses. The Ad.ASbFGF
replication-defective recombinant adenovirus was
constructed by replacement of the β-galactosidase
cDNA with a 1.1 kbp rat bFGF cDNA that con-
tained the entire coding sequence in reverse orienta-
tion (gift of Dr Andrew Baird, Whittier Institute)12
in the plasma AD.CMV laZ (Ad.lacZ) shuttle vector
(gift of Dr James Wilson, University of
Pennsylvania) followed by homologous recombina-
tion13 with the E1, E3-deleted, human adenovirus
serotype 5 mutant dl700114 in human embryonal
kidney 293 cells (American Type Culture
Collection, Bethesda, Md). Recombinant virus was
identified by polymerase chain reaction (PCR)
amplification of recombinant plaques with the use of
one vector-specific and one insert-specific primer.
The vector-specific primer (5´-AGA-CAT-GAT-
AAG-ATA-CAT-3´) corresponds to a region of the
plasmid shuttle vector upstream of the insert cloning
site but contains no adenoviral genomic sequence.
The insert-specific primer (5´-GCT-TCT-TCC-
TGC-GCA-TCC-3´) corresponds to codons 37 to
42 of the rat bFGF coding sequence. The recombi-
nant virus was twice plaque-purified, and the expres-
sion of the antisense transcript was confirmed by
reverse transcriptase PCR (RT-PCR). The PCR was
performed with 1 U per reaction of Taq polymerase
(Boehringer Mannheim Corp, Indianapolis, Ind) in
a thermal cycler (Ericomp Inc, San Diego, Calif) for
25 cycles with 1-minute steps. The denaturation was
performed at 94°C; the annealing was performed at
60°C, and the extension was performed at 72°C.
Ad.lacZ was used as the viral vector control in
these experiments. The suspension vehicle (PBS Bio-
Whittaker, Walkersville, Md) served as the second
control. Adenovirus that carried a cassette that encod-
ed bFGF was not used as a control because it pro-
duces a protein with biologic effects. Importantly, the
RNA produced by Ad.ASbFGF serves as an effective
block of bFGF protein synthesis as demonstrated in
SMC culture by Western immunoblot analysis.10
Experimental groups 
RNA was extracted from grafts harvested at 2
days, 1 week, 2 weeks, and 4 weeks to study the time
course of bFGF expression in untreated AVGs.
Three grafts were harvested for each time point.
Ungrafted veins and carotid arteries were obtained
at the time of death from the 2-day rabbits.
Animals were randomly assigned to three treat-
ment groups (one experimental and two control
groups) to test whether antisense bFGF RNA had an
effect on vein graft wall remodeling. Each treatment
group consisted of 13 rabbits that received either
Ad.ASbFGF at 1 × 1010 PFU/mL, Ad.lacZ at 1 ×
1010 PFU/mL, or PBS (vehicle only). The dose of
Ad.ASbFGF was chosen because it provides benefi-
cial effects in a carotid artery injury model.11
Analysis of bFGF RNA time-course in untreated
AVGs
Untreated AVGs were harvested at 2 days, 1 week,
2 weeks, and 4 weeks and snap-frozen in liquid nitro-
gen. Ungrafted jugular veins and normal carotid
arteries were also harvested. Samples were homoge-
nized, and the RNA was extracted with RNAzol B
according to the manufacturer’s instructions (Biotecx
Laboratories, Houston, Texas). Total tissue RNA (2
µg) was heat denatured (65°C for 5 min) and reverse-
transcribed with 0.1 µg of random hexamer primers
(Boehringer Mannheim Corp) and 400 units of
Moloney murine leukemia virus reverse transcriptase
(Gibco BRL, Gaithersberg, Md). Incubation was for
1 hour at 37°C in 50 µL reverse transcriptase buffer.
The reaction was terminated when the mixture was
heated to 95°C for 10 minutes. 
All cDNA products were amplified with 0.25 µg
of each primer and 25 units of Taq DNA polymerase
(Boehringer Mannheim Corp). Normal carotid
artery served as the positive control, and RNA-free
water served as negative control. The sequences of
the human bFGF primers were as follows, 5´
ACCATGGCAGCCGGGAGCATCACCACGCTG
3´ (sense) and 5´ CAGCTCCTTAGCAGACATTG-
GAAGAAAAAG 3´ (antisense). These primers are
predicted to amplify a 471-bp fragment. PCR was
performed in a thermal cycler (Perkin Elmer 9600;
Perkin Elmer, Norwalk, Conn) for 35 cycles with
30-second steps. Denaturation was performed at
94°C; annealing was performed at 58°C, and exten-
sion was performed at 72°C. An aliquot of each
amplification mixture was subjected to electrophore-
sis on 2% agarose gel and was visualized by the
Southern blot technique.
Tissue preparation and analysis 
X-gal chromagen staining. Two animals from
each treatment group were killed at 4 days after the
grafting procedure. Tissue samples were quickly har-
vested, rinsed of blood, embedded in OCT com-
pound (Miles Inc, Elkhart, Ind), and frozen with
dry ice. The uninjured right external jugular veins
served as negative controls for gene transfer.
β-Galactosidase activity, an index of successful
Ad.lacZ infection, was documented with X-gal chro-
magen in interposition AVG specimens. Vein graft
samples were thawed and rinsed with PBS to remove
OCT. The tissues were immersed in PBS for 20 min-
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utes, then fixed in 2.5% glutaraldehyde (Fisher
Scientific, Fair Lawn, NJ) for 15 minutes. Samples
were rinsed twice in 1 mmol/L MgCl-PBS before
incubation with the X-gal chromagen mixture (5-
Bromo-4-chloro-3-Indolyl-β-D-galactopyranoside;
Fisher Scientific, Malvern, Pa) for 1 hour at 37°C.
Cross-section and enface preparations were exam-
ined at ×10 and ×25 with a Leitz dissecting pho-
tomicroscope (Leica Inc, Malvern, Pa). 
After X-gal chromagen staining, a segment of vein
was also fixed in 10% formalin and embedded in
paraffin. Eight micrometer-thick cross section samples
were cut from the paraffin blocks, counterstained with
hematoxylin, then examined at ×250 magnification
(Leitz Laborlux-s; Leica Inc) for evidence of intracel-
lular production of β-galactosidase. Tissues that
stained positive for β-galactosidase contained blue
cytoplasmic inclusions. Only blue staining adjacent to
a nucleus was counted as a β-galactosidase positive cell
to avoid overestimation of efficiency. Results were
recorded as percent efficiency of transgene expression.
The mean percent efficiency of transgene expression
was calculated by averaging the number of β-galac-
tosidase positive cells divided by the number of total
cells in the intima and media per ×250 field.
Determinations were made at six randomly chosen
sites on each cross section with reference to position
on a clock face. Four individual cross sections were
examined per AVG, and two separate AVGs were
examined per treatment group. 
Documentation of ASbFGF gene transfer to
arterialized vein graft tissue. Confirmation of suc-
cessful vein graft infection by the Ad.ASbFGF vector
was documented with RT-PCR. Ad.ASbFGF- and
Ad.lacZ-infected grafts were harvested 3 days after
the experimental procedures. Naive ungrafted, unin-
fected anterior jugular vein served as a negative tissue
control. The complement DNA plasmid encoding
the antisense bFGF sequence that was used initially
to make the Ad.ASbFGF vector served as the PCR-
positive control. RT-PCR was performed with the
following steps:
1. RT: Three AVGs from each vector-treated group
and normal vein were weighed and homogenized
with Trizol (1 mL per 50-100 mg tissue; Gibco-
Life Science, Gaithersburg, Md). Manufacturer’s
instructions were followed for phase separation,
RNA precipitation, and redissolution of the
RNA. Ultraviolet spectrophotometry at 260 nm
and 280 nm was used to measure the RNA con-
centration and purity of each sample. Total tissue
RNA (3 µg) was heat denatured (65°C for 5 min)
and reverse-transcribed with 1 µmol of a
sequence-specific primer. This primer contains 18
bases (5´-ACTTCGCTTCCCGCACTG-3´) of
bFGF sequence complementary to the antisense
strand (corresponding to codons 7-12 of 18-kD
rat bFGF at the 3´ end and a 30-base random
sequence at the 5´ end (5´-CTTATACG-
GATATCCTGGCAATTCGGACTT –3´). The
5´ random sequence tag permits subsequent PCR
amplification with a specific primer that corre-
sponds to this tag sequence, thus rendering the
overall amplification both strand-specific and ade-
novirally mediated RNA specific. RT was per-
formed in a final reaction volume of 30 µL with
the use of 20 units of RT (Perkin Elmer).
Incubation conditions for RT were 15 minutes at
42°C, 30 minutes at 37°C, and 5 minutes at
95°C in a thermal cycler (Perkin Elmer 480;
Perkin Elmer).
2. PCR: All cDNA products were amplified with 1
pmol of the tag sequence plus 1 pmol of a spe-
cific primer for 18-kD reverse bFGF codons.
Antisense bFGF cDNA plasmid served as the
positive control. Normal vein and RNA-free
water served as negative controls. The target RT
products were amplified with 1 pmol each of the
tag primer plus the primer sequence (that was
described earlier) in the tissue RT reaction. The
PCR was performed in a 20 µL volume with 1
unit per reaction of Taq polymerase (Perkin
Elmer) in a thermal cycler (Perkin Elmer 9600;
Perkin Elmer) for 25 cycles with 1-minute steps
(Perkin Elmer). Denaturation was performed at
94°C; annealing was performed at 60°C, and
extension was performed at 72°C. Products were
separated on an agarose gel and visualized by
ethidium bromide staining with a digital imaging
system (IS-1000; Alpha Innotech Corp, San
Leandro, Calif). If ASbFGF transcript is present,
a 428-bp PCR product should be identified.15
Formalin fixation. The remaining eight ani-
mals in each treatment group were killed at 3 weeks
(n = 3 animals) or 2 months (n = 5 animals) after
injury. At these times, the vessels were perfusion
fixed in situ at a perfusion pressure of 100 to 110
mm Hg. Normal saline solution was instilled first
and followed by 10% formalin solution through a
large-bore cannula that was placed retrograde in the
thoracic aorta. The carotid arteries that contained
the interposition vein grafts were harvested en bloc
for further immersion fixation. The samples were
embedded in paraffin then processed with either
hematoxylin-eosin or elastin-collagen stain. All
chemicals were of analytic-grade quality.
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BFGF immunohistochemistry. Three samples
from the 3-week-old groups and five samples from
the 2-month-old groups were analyzed for the pres-
ence of bFGF protein. Three-week-old AVGs were
evaluated because the adenoviral vector is almost
completely absent after 10 to 14 days. At 3 weeks,
the grafts have the morphologic characteristics that
persist at least up to 2 months. However, the effect
of the antisense RNA on bFGF synthesis may still be
noticeable at 3 weeks. 
Paraffin-embedded 6-µm thick cross sections
were deparaffinized in xylene and hydrated through
graded ethanol baths. The slides were prepared in the
microwave in SMC 1X buffer (Promega Corp,
Madison, Wis) for 30 seconds and left in the hot
solution for 30 minutes. Antigen retrieval was per-
formed with 0.2% hyaluronidase (Sigma Corp, St
Louis, Mo) in PBS at 37°C for 30 minutes.
Endogenous peroxidase was blocked with 3% H2O2
for 10 minutes. Primary antibody to bFGF at a dilu-
tion of 1:100 (Upstate Biotechnology, Waltham,
Mass) was incubated at room temperature for 2
hours. Biotinylated goat–anti-mouse secondary anti-
body was incubated at room temperature for 30 min-
utes (BioGenex, San Ramon, Calif). Application of
the horseradish peroxidase label and chromagen
developer was as per instructions in the detection kit
(BioGenex “Supersensitive”: BioGenex).
Morphometric analysis of the AVG wall
Tangential stress (lumen radius to wall thick-
ness ratio). Morphometric analysis was performed
on AVG cross sections. Measurements were per-
formed with a light microscope (Leitz Laborlux-s;
Leica Inc), fitted with a computer-interfaced image
analyzer (Bioquant System IV; R&M Biometrics
Inc, Nashville, Tenn; and Summa Sketch II Plus;
Summagraphics Corp, Seymour, Conn). The cir-
cumference of the AVG lumen was directly mea-
sured at a magnification of ×50. Three separate cross
sectional samples (proximal, mid, and distal regions)
were measured from each graft to determine the
luminal radius.
Mean tangential stress across the wall may be
estimated from the LaPlace law τT = Pr/h, where τ
is tangential wall stress, P is systemic pressure, r is
luminal radius, and h is vessel wall thickness. If blood
pressure is constant, then mean tangential stress is
proportional to the r/h ratio.4
Wall thickness measurement. Total wall thick-
ness was measured at nine sites (at designated clock
positions) on each cross section sample. Three cross
sectional samples were evaluated for each graft (one
each from the proximal, mid, and distal AVGs). The
mean wall thickness was calculated by averaging the
thickness of the nine sites on each cross section then
averaging the results of the three cross sections from
each AVG. Wall thickness was defined as the region
from the lumen up to where abluminal microvessels
were observed (the adventitia). An arbitrary number
was assigned to each sample, thereby blinding the
person performing the measurements to the treat-
ment and original sample designation. All measure-
ments were performed in duplicate.
Statistical analysis
Data were calculated for each group as mean ±
SD of the mean and were compared with one anoth-
er by analysis of variance, followed by the Tukey
method of post hoc pair-wise testing. The data were
computed with the Systat 5.01 for Windows soft-
ware (Systat Incorporated, Evanston, Ill). A P value
of .05 or less was considered significant.
RESULTS
Time course of bFGF upregulation in AVGs.
Fig 1 shows the results of the investigation of the
changes in bFGF RNA in the rabbit AVG. Normal
Fig 1. RT-PCR for bFGF RNA in normal carotid artery
(lane 1), native jugular vein (lane 2), 2-day-old vein graft
(lane 3), 1-week-old vein graft (lane 4), 2-week-old vein
graft (lane 5), and 4-week-old vein graft (lane 6). Note
that bFGF RNA is not detectable in native jugular vein
and in the 2-day-old graft. It is present at 1 week and
thereafter. The results are not quantitative because the
goal of the study was simply to demonstrate the detection
of or the lack of RNA (cDNA products). Lane overload-
ing is responsible for the cDNA product smear observed
in some lanes. 
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carotid arteries contain messages for bFGF, although
RNA for bFGF was not detected in native jugular vein
or in the jugular vein graft at 2 days after grafting.
There is detectable upregulation of bFGF RNA in the
grafted veins at 1 week after grafting and thereafter. 
Ad.lacZ transgene expression. AVGs, processed
with X-gal chromagen for β-galactosidase, demon-
strates excellent gene transfer with Ad.lacZ (Fig 2, A).
Sixty-five percent of AVG intima and media cellular
elements stained positively for β-galactosidase activity
(Fig 2, B). Positive X-gal chromagen reaction was
detected in the cells of the media and extended trans-
murally, in some sites, deeply into the bordering
adventitia. This observation demonstrates the depth
of AVG wall penetration achieved by adenovirally
mediated gene transfer. Endogenous β-galactosidase
activity was not detected in PBS or Ad.ASbFGF-treat-
ed AVGs or in native vein.
Ad.ASbFGF transgene expression and its
impact on bFGF production. Gene expression of an
ASbFGF RNA at 3 days after infection and grafting was
noted only in the Ad.ASbFGF-treated grafts and not in
control samples (Fig 3). Both Ad.ASbFGF-treated
grafts and plasmid cDNA (positive control) yielded an
identical cDNA product (428 bp), although Ad.lacZ
and PBS did not show ASbFGF RNA expression. 
Expression of ASbFGF RNA in the AVGs
reduced bFGF protein expression at 3 weeks (Fig 4,
A) relative to control (Fig 4, B). Because the
ASbFGF is degraded by day 14, there is a more
modest reduction of bFGF protein expression in the
AVGs treated with Ad.ASbFGF (Fig 4, C) relative to
control at 2 months (Fig 4, D).
Vein graft wall histologic features. A hallmark
of AVG is wall thickening. The difficulty in unequivo-
cally identifying the internal elastic lamina and the
inconsistent demarcation of the external elastic lamina
precluded us from accurately measuring neointima and
Fig 2. A, Luminal view of the Ad.lacZ-treated vein graft at 4 days after grafting (original mag-
nification, ×3). The carotid artery is above the anastomosis; the graft is below. Note the dense
blue patches on the luminal surface in the vein graft after X-gal chromagen staining, which
indicates the expression of the β-galactosidase transgene. B, Cross-sectional view of an
Ad.lacZ-treated vein graft. Dark blue inclusions demonstrate β-galactosidase staining, which is
transmural in some regions. Sixty-five percent of vein graft wall cells express the β-galactosi-
dase transgene (original magnification, ×250). Nuclei were counterstained with hematoxylin.
A
B
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media separately. The presence of capillaries and other
vascular structures located only in the adventitia served
as the operational criteria for the determination of the
medial/adventitial border in all these grafts. 
The neointima of the PBS and Ad.lacZ-treated
AVGs appeared granular (with elastin fibers, cells,
and matrix oriented at arbitrary angles to each other;
Fig 5, A and B). In contrast, Ad.ASbFGF-treated
grafts thickened by developing layers of circumfer-
entially oriented SMCs and elastin fibers, much like
that seen in normal arteries. It is not clear whether
these parallel SMCs occupy space in the “neointima”
or are a component of the media (Figs 5, C, and 6).
Statistical analysis for tangential stress, wall
thickness, and lumen circumference. There was a
significant difference in mean total wall thickness
among the three treatment groups (Ad.ASbFGF, 164
± 3.4 µm; Ad.lacZ, 100 ± 3.3 µm; and PBS, 96 ± 3.6
µm; P < .1; Table I). There was no significant differ-
ence in mean lumen circumference among the treat-
ment groups (Table II), which implied that wall thick-
ening does not occur at the expense of luminal diam-
eter. Grafts treated with Ad.ASbFGF displayed lower
tangential stress ratio (10.9 ± 2.3 dynes/cm2) when
compared with PBS alone (22 ± 2.8 dynes/cm2) or
Ad.lacZ-treated controls (20.6 ± 5.4 dynes/cm2; P <
.001). Tangential stress in the Ad.ASbFGF group is
comparable to normal carotid artery (13.9 ± 2.1
dynes/cm2; Table III). 
DISCUSSION
Our study demonstrates that the inhibition of
bFGF synthesis in AVGs, with the use of an antisense
RNA gene strategy, significantly decreases tangential
wall stress. This reduction is effective and has poten-
tial physiologic significance because the Ad.ASbFGF-
treatment of AVGs changes the calculated tangential
wall stress to be comparable to that of normal carotid
arteries. 
The reduction in calculated wall stress in
Ad.ASbFGF-treated AVGs is most likely the result of
the thickening of the vein wall. This morphologic
change is an element of the adaptive response of
interposition vein grafts to the sudden alteration in
normal stress and is characterized by thickening as
the result of SMC proliferation and extracellular
matrix deposition.4,16 In our study, mean wall thick-
ness was significantly increased in Ad.ASbFGF-treat-
ed veins relative to PBS- and Ad.lacZ-treated grafts,
although the lumen, and therefore the radius,
remained comparable in all the groups. In addition,
thickening of the ASbFGF-treated AVGs occurred
with the cellular and matrix fibers aligned concentri-
cally around the lumen, whereas this pattern was
absent in Ad.lacZ- and PBS-treated AVGs. In agree-
ment with earlier reports,4,16 vein wall thickening in
the rabbit AVG appears to occur without compro-
Fig 3. The expression of ASbFGF RNA in 3-day-old
Ad.ASbFGF-treated vein grafts. RT was performed on
total RNA extracted from Ad.ASbFGF-, Ad.LacZ-, and
PBS-treated vein grafts. Only Ad.ASbFGF-treated grafts
are depicted here with positive and negative controls. Lane
1 contains a base-pair ladder. Lane 3 contains the positive
control and demonstrates the cDNA product obtained by
the use of the ASbFGF plasmid as a PCR template. This
plasmid was used to make the Ad.ASbFGF vector. Lane 4
contains the amplification cDNA product of 3-day-old
Ad.ASbFGF-infected vein grafts. The primary product
(arrow) is the same (428 bp) as the plasmid positive con-
trol. Lane 5 demonstrates that amplification of the
ASbFGF transgene in ungrafted veins yields no product.
Lane 6 shows no ASbFGF transgene in RNAse-free water.
PCR cDNA products are visualized on agarose gels
stained with ethidium bromide. Lane 2 is empty.
Table I. Mean wall thickness ± SD (n = 5 animals)
Treatment 2-month vein graft (µm)
PBS 96 ± 3.6
Ad.lacZ 100 ± 3.3
Ad.ASbFGF 164 ± 3.4*
*P < .01 vs PBS and Ad.lacZ.
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mising lumen diameter. Our results confirm this
form of tissue remodeling in rabbit interposition
AVGs. In addition, our data advance the concept
that early inhibition of bFGF provides potentially
beneficial effects on tissue remodeling. 
Earlier reports showed upregulation of bFGF in
injured arteries.9 We reasoned that augmentation of
gene expression of bFGF may also occur in interpo-
sition AVGs. We examined the level of RNA for
bFGF in untreated-AVGs and demonstrated here
that indeed bFGF is upregulated after grafting.
Interestingly, the levels of bFGF RNA are unde-
tectable in naive jugular vein, and upregulation takes
longer than 2 days after grafting. Our work and the
work of others16 have established that untreated
AVGs in animal models will degenerate in time,
which has been noted also in human autogenous
vein grafts.17 However, normal rabbit carotid arter-
ies show significant levels of bFGF, as do maturing
untreated AVGs (Fig 1). These apparently opposite
observations lead to the hypothesis that bFGF may
play different roles in normal arteries and in remod-
Table III. Mean tangential stress ± SD
2-month vein Normal carotid 
Treatment n graft (dynes/cm2) artery (dynes/cm2)
PBS 5 22.0 ± 2.8
Ad.lacZ 5 20.6 ± 5.4
Ad.ASbFGF 5 10.9 ± 2.3*
None 6 13.9 ± 2.1*
*P < .001 vs PBS and Ad.lacZ.
Table II. Mean lumen circumference ± SD (n = 5
animals)
Treatment 2-month vein graft (mm)
PBS 12.2 ± 3
Ad.lacZ 12.2 ± 2
Ad.ASbFGF 11.3 ± 2
Fig 4. Immunohistochemistry for basic FGF protein in 3-week-old and 2-month-old vein
grafts. At 3 weeks the thickened wall of vein grafts treated with Ad.ASbFGF shows minimal
staining for bFGF protein (A), although the Ad.lacZ and PBS grafts stain heavily for bFGF
protein (B; original magnification, ×125). 
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eling AVGs. One would speculate that bFGF may
participate actively in the remodeling of arteries in
response to high shear stress and pulsatile flow. On
the other hand, observations in tissue culture indi-
cate that ASbFGF inhibits the growth rate of
ASbFGF-infected SMCs in a dose-dependent fash-
ion.10 Furthermore, those observations suggested
that ASbFGF may have led to apoptosis in tissue cul-
ture, as indicated by TUNEL reaction and by gel
electrophoresis. Importantly, supplementing the
growth medium with recombinant bFGF can restore
the SMC growth rate.10 However, the molecular
mechanisms of action of inhibition of bFGF on
AVGs are not the subject of our current report.
Success of transfection of antisense bFGF RNA in
our study was demonstrated indirectly by β-galactosi-
dase activity and directly by the presence of a 428-bp
cDNA product by RT-PCR and by the inhibition of
bFGF protein synthesis in AVGs at 3 weeks and at 2
months after the transfection and grafting. These find-
ings support the existence of a cause-effect relationship
between inhibition of bFGF and the observed wall
thickening and the maintenance of lumen circumfer-
ence, with reduction in calculated tangential wall
stress. Whether bFGF directly modulates the remodel-
ing process or stimulates the synthesis/release of other
mediating agents remains to be elucidated. 
We opted to use an adenoviral vector that has a
short half-life. The reasons for selecting this vector
are (1) the vector itself is engineered to be replica-
tion deficient, (2) the transgene does not incorpo-
rate into the host genome, and (3) the immune sys-
tem of the host eventually destroys the adenovirus.18
The transgene is present for only 10 to 14 days in
our rabbit model, but the results of this study show
a sustained effect in the alteration of the remodeling
process, at least up to 2 months after the transfection
and grafting. Therefore the major potentially bene-
ficial effects of the ASbFGF must take place or be
initiated during those first 2 weeks after the grafting. 
In summary, we have demonstrated that the inhi-
bition of bFGF reduces tangential stress and pro-
motes the orderly arrangement of cells and matrix in
the AVG wall. These potentially beneficial effects are
sustained for at least 2 months. We propose that ade-
novirally mediated ASbFGF gene therapy offers a sin-
gle, local treatment that may represent an effective
strategy in limiting vein graft failure. 
Fig 4 Cont’d. At 2 months, an appreciable reduction in bFGF staining persists in the
Ad.ASbFGF-treated grafts (C) compared with control grafts (D), although the difference is
not as notable (original magnification, ×250). All nuclei were counterstained with hema-
toxylin.
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